Shenderov B.A. Microbial ecology of man and its role in maintaining health. Metamorphoses. 2014(3): 72-80.
Khachatrian R., Khachatrian A. Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men. US Patent 6428783 C12N 1/04, 2002
Borody T., Warren E., Leis S., Surace R., Ashman O., Siarakas S. Bacteriotherapy using fecal flora: toping with human motions. J. Clin. Gastroenterol. 2004; 38(6): 475-83.
Debast S.B, Bauer M.P, Kuijper E.J. On behalf of the Committee. European Society of Clinical Microbiology and Infectious Diseases: update for the treatment guidance document for Clostridium difficult infection. Clin Microbiol Infect. 2014; 20 (Supply 2): 1-26.
Bakken J.S. Feces transplantation for recurrent Clostridium difficile infection: US experience and recommendations. Microb. Ecol. Health Dis. 2015, 26: 27657.
Carlucci C., Petrof E.O., Allen-Vercoe E. Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile infection, Ulcerative Colitis and Obesity. EBioMedicine. 2016. http://dx.doi.org/10.1016/J.ebiom.2016.09.029
Hyun Ho Choi, Young-Seok Cho. Fecal Microbiota translation: Current Applications, Effectiveness, and Future Perspectives. Clin. Endosc. 2016; 49: 257-265.
Nibali L., Henderson B. The Human Microbiota and Chronic Disease: Dysbiosis as a cause of Human Pathology. First Edition. 2016 John Wiley & Sons, Inc. New Jersey, USA, 520 pages.
Fak F. The gut microbiota: a predisposing factor in vanity, diabetes and atherosclerosis. Chapter 23. In: The Human Microbiota and Chronic Disease: Dysbiosis as a cause of Human Pathology. First Edition. 2016. John Wiley & Sons, Inc. New Jersey, USA; 351-359.
Lo Vecchio a., Guarino A. The microbiota as target for therapeutic intervention in pediatric intestinal diseases. Chapter 31. In: The Human Microbiota and Chronic Disease: Dysbiosis as a cause of Human Pathology. First Edition. 2016. John Wiley & Sons, Inc. New Jersey, USA; 483-496.
Bruzzese E., Buccigrossi V., Ranucci G., Guarino A. Microbial therapy for cystic fibrosis. Chapter 32. In: The Human Microbiota and Chronic Disease: Dysbiosis as a cause of Human Pathology. First Edition. 2016. John Wiley & Sons, Inc. New Jersey, USA; 497-506.
Kazerouni a., Burgess J., Burns L.J., Wein L.M. Optimal screening and donor management in a public stool bank. Microbiome 2015; 3: 75. doi 10.1186/s40168-015-0140-3
Shenderov B.A., gakhova E.N., kaurova S.A., Uteshev V.K., Shishova R.V. Cryobanks natural simbioticheskoi of microbial associations and their importance in medicine and biotechnology. Biophysics of living cells. 2014(10): 221-223.
Bezrodny S.L., Shenderov B.A. Intestinal microbiota as a source of new biomarkers of aging. Journal of restorative medicine & rehabilitation. 2015(2): 40-47.
Shenderov BA. Microecological epigenetics of stress, diseases, health and longevity. Journal of restorative medicine & rehabilitation. 2016(1): 21-28.